Navigation Links
Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
Date:6/1/2009

- Interim Primary Endpoint Data from Phase II Study Shows 71% Objective Tumor Response Rate in Evaluable Patients Receiving Bavituximab Plus Docetaxel -

- Secondary Endpoint Evaluation Shows Promising 7.4 Month Median Progression Free Survival in Initial Study Cohort -

ORLANDO, Fla. and TUSTIN, Calif., June 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that preliminary results from a Phase II trial of its lead anti-phosphatidylserine antibody bavituximab in combination with docetaxel in patients with advanced breast cancer will be discussed this morning in an oral presentation at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). Initial data from the Phase II study indicates that 10 of 14 evaluable patients in the first cohort of the trial achieved an objective tumor response by the end of the treatment period according to RECIST criteria. Recent analysis shows the median progression free survival of the patients enrolled in the first part of the study was 7.4 months.

Bavituximab is a monoclonal antibody with a unique anti-cancer mechanism that works by helping to activate the body's own immune system to fight cancer. Bavituximab binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed specifically on the outside of cells that line tumor blood vessels. Once bound to the exposed PS, bavituximab helps mobilize the body's immune system to destroy both the tumors and their associated blood vessels.

"The preliminary data in this first cohort of advanced breast cancer patients treated with bavituximab and docetaxel along with data we have generated from the two other ongoing Phase II bavituximab cancer trials is very encouraging and suggests that bavituxi
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
2. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
3. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
4. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
5. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
6. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
7. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
8. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
9. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
10. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
11. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Vala Sciences was recently awarded ... Agency (EPA). This new contract was awarded for ... tests designed to assess the effect of chemical ... connections between neurons (synapses), which are critical for ... by environmental pollutants likely contributes to a variety ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
(Date:7/29/2014)... number of significant technological challenges in their quest ... created for the James Webb Space Telescope. , ... a scientist at NASA,s Goddard Space Flight Center ... microshutter arrays that is, those activated by ... as the current technology,s magnetically activated arrays. This ...
(Date:7/29/2014)... Human Longevity, Inc. (HLI), a genomics and ... the healthy, high performance human life span, today announced ... expert in machine learning and machine translation as the ... Google where he was Distinguished Research Scientist and the ... HLI Co-Founder and CEO, J. Craig Venter , ...
Breaking Biology Technology:U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3
... ,60s cleanup of toxic pollution in Seattle,s ... Lake Washington, ... but sometimes, at least in the case of a little fish called ... study led by researchers at Fred Hutchinson Cancer Research,Center and published online ...
... KV is Now Offering The Complete Line of All Four ... ... the 50 mg ... KVa/KVb), a fully integrated specialty pharmaceutical company that,develops, manufactures, acquires ...
... BALTIMORE, May 15 Lentigen Corporation announced today,that ... (NIH) small,business innovation research (SBIR) grants to collaborate ... its proprietary,lentiviral vector (LV) technology to the development ... medical need:, -- Melanoma, with Michael ...
Cached Biology Technology:Researchers Document Rapid, Dramatic 'Reverse Evolution' in the Threespine Stickleback Fish 2Researchers Document Rapid, Dramatic 'Reverse Evolution' in the Threespine Stickleback Fish 3Researchers Document Rapid, Dramatic 'Reverse Evolution' in the Threespine Stickleback Fish 4KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R) 2KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R) 3KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R) 4Lentigen Corporation Receives Four Research Grants From the National Institutes of Health 2
(Date:7/30/2014)... today published new research from Bjorn Brembs, professor of ... Germany, with a proof-of-concept figure allowing readers and reviewers ... This represents an important leap forward for scientific ... the quality of a scholarly output. , Figure 3 ... data and their code to F1000Research , and ...
(Date:7/30/2014)... injury (SCI), traumatic brain injury (TBI) and peripheral nerve ... learned over the past 30 years regarding both the ... growth, but this large body of information has not ... his team from University of Miami in USA proposed ... consensus is emerging that one contributing factor is a ...
(Date:7/30/2014)... journal Scientific Reports , published by Nature ... that while global temperature is indeed increasing, so too ... each year,s average hottest and coldest temperatures will likely ... a wider range of potential high and low temperate ... even as overall temperatures rise, we may still continue ...
Breaking Biology News(10 mins):F1000Research brings static research figures to life 2Big data confirms climate extremes are here to stay 2
... DURHAM, N.C. Under the microscope, the bacteria start dividing ... on. But then individual cells begin "popping," like circus balloons ... Duke University bioengineers who captured it on video, turns out ... must be considered by scientists creating living, synthetic circuits out ...
... professor Kam Tang of the Virginia Institute of Marine ... fleas" play an important role in carrying hitchhiking bacteria ... article, "Bacteria dispersal by hitchhiking on zooplankton," appeared in ... the National Academy of Sciences . It was co-authored ...
... - Greenhouse gas markets, where invisible gases are ... people. Farmers can make money on these markets, ... methane capture technologies in animal-based systems, no-till farming, ... extension educators, offset aggregators, and other stakeholders need ...
Cached Biology News:Popping cells surprise living circuits creators 2Popping cells surprise living circuits creators 3Study shows that hitchhiking bacteria can go against the flow 2Study shows that hitchhiking bacteria can go against the flow 3Greenhouse gas calculator connects farming practices with carbon credits 2